{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:08:30Z","timestamp":1793419710139,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcpo.2026.100728","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:20:08Z","timestamp":1772126408000},"page":"100728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluating the economic burden of bladder cancer in 32 European countries using a value of a statistical life year framework"],"prefix":"10.1016","volume":"48","author":[{"given":"Goran","family":"Bencina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Aste","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcpo.2026.100728_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.eururo.2025.02.005","article-title":"Why we need more attention on bladder cancer: establishing policy recommendations for health care professionals and politicians","volume":"87","author":"Ecke","year":"2025","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.jcpo.2026.100728_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jcpo.2026.100728_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115621","article-title":"Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in Germany","volume":"227","author":"Rieger","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jcpo.2026.100728_bib4","first-page":"3578","article-title":"SunRISe-1 Study. TAR-200 for Bacillus Calmette-Gu\u00e9rin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study","volume":"43","author":"Daneshmand","year":"2025"},{"key":"10.1016\/j.jcpo.2026.100728_bib5","article-title":"Perioperative durvalumab plus chemotherapy in muscle-invasive bladder cancer: the NIAGARA Phase 3 Trial","volume":"43","author":"Powles","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.jcpo.2026.100728_bib6","first-page":"1352","article-title":"Pembrolizumab plus enfortumab vedotin in previously untreated advanced urothelial carcinoma","volume":"389","author":"Rosenberg","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2026.100728_bib7","doi-asserted-by":"crossref","unstructured":"OECD (2012), Mortality Risk Valuation in Environment, Health and Transport Policies, OECD Publishing.http:\/\/dx.doi.org\/10.1787\/9789264130807-en.","DOI":"10.1787\/9789264130807-en"},{"key":"10.1016\/j.jcpo.2026.100728_bib8","unstructured":"Eurostat, Causes of death: deaths by country of residence and occurence mortality data 2024. \u3008https:\/\/ec.europa.eu\/eurostat\/web\/main\/data\/database\u3009 (Accessed March 2025)."},{"key":"10.1016\/j.jcpo.2026.100728_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2024.100499","article-title":"The productivity cost of mortality due to lung cancer, breast cancer and melanoma in Europe across 2010, 2015 and 2019","volume":"42","author":"Brandtm\u00fcller","year":"2024","journal-title":"J. Cancer Policy"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100728_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09581596.2024.2333407","article-title":"The economic burden of obesity in 2024: a cost analysis using the value of a statistical life","volume":"34","author":"Sweis","year":"2024","journal-title":"Crit. Public Health"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100728_bib11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic Burden of Bladder Cancer Across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.jcpo.2026.100728_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.euo.2024.10.003","article-title":"Cost-effectiveness analysis in the new era of treatment strategies in metastatic urothelial carcinoma based on checkmate-901 and EV302\/Keynote-A39","volume":"8","author":"Rieger","year":"2025","journal-title":"Eur. Urol. Oncol."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:48:10Z","timestamp":1783025290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":12,"alternative-id":["S2213538326000287"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100728","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the economic burden of bladder cancer in 32 European countries using a value of a statistical life year framework","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100728"}}